Imatinib was successfully used in a large inoperable MCC in a 92-year-old patient [204] but in a phase II trial where imatinib was used as a targeted molecular therapy for MCCs that express CD117 (c-KIT) protein, little efficacy was observed, suggesting that further active and tolerable agents need to be developed for MCC [205]. The gene discussed is KIT; the disease is Merkel cell skin cancer.